Table 5. Adverse effects during treatmenta.
| Unadjusted | Adjustedb | |||||
|---|---|---|---|---|---|---|
| Adverse effect | Control | Magnesium | Difference | Difference | 95% CI | P |
| Headache | 0.57 | 0.41 | -0.16 | -0.14 | -0.25, -0.03 | 0.01 |
| Diarrhea | 0.32 | 0.29 | -0.02 | -0.01 | -0.11, +0.08 | 0.79 |
| Nausea | 0.22 | 0.24 | +0.02 | +0.02 | -0.07, +0.11 | 0.64 |
| Constipation | 0.20 | 0.20 | +0.00 | -0.00 | -0.08, +0.07 | 0.97 |
| Dizziness | 0.24 | 0.22 | -0.02 | -0.02 | -0.09, +0.06 | 0.66 |
| Oliguria | 0.04 | 0.07 | +0.03 | +0.03 | -0.02, +0.08 | 0.19 |
| Polyuria | 0.11 | 0.16 | +0.05 | +0.05 | -0.01, +0.11 | 0.09 |
CI = confidence interval.
aMean values of biweekly reports on a 0 to 4 scale.
bAdjusted for mean PHQ-9 score during control weeks, treatment order (Immediate vs. Delayed), use of SSRIs, and clustering within participant.